- Home
- KROS vs EU Comparison
KROS vs EU Comparison
Compare KROS & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- EU
- Stock Information
- Founded
- KROS 2015
- EU 2009
- Country
- KROS United States
- EU United States
- Employees
- KROS N/A
- EU N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- EU Other Metals and Minerals
- Sector
- KROS Health Care
- EU Basic Materials
- Exchange
- KROS Nasdaq
- EU Nasdaq
- Market Cap
- KROS 565.0M
- EU 445.3M
- IPO Year
- KROS 2020
- EU N/A
- Fundamental
- Price
- KROS $15.55
- EU $2.52
- Analyst Decision
- KROS Buy
- EU Strong Buy
- Analyst Count
- KROS 14
- EU 1
- Target Price
- KROS $20.56
- EU $4.00
- AVG Volume (30 Days)
- KROS 417.3K
- EU 4.9M
- Earning Date
- KROS 11-05-2025
- EU 11-13-2025
- Dividend Yield
- KROS N/A
- EU N/A
- EPS Growth
- KROS N/A
- EU N/A
- EPS
- KROS 0.47
- EU N/A
- Revenue
- KROS $232,844,000.00
- EU $44,524,000.00
- Revenue This Year
- KROS $5,579.44
- EU $33.35
- Revenue Next Year
- KROS N/A
- EU $112.45
- P/E Ratio
- KROS $33.52
- EU N/A
- Revenue Growth
- KROS 85820.30
- EU N/A
- 52 Week Low
- KROS $9.12
- EU $1.01
- 52 Week High
- KROS $72.37
- EU $4.44
- Technical
- Relative Strength Index (RSI)
- KROS 57.26
- EU 53.54
- Support Level
- KROS $15.23
- EU $2.26
- Resistance Level
- KROS $15.85
- EU $2.37
- Average True Range (ATR)
- KROS 0.48
- EU 0.13
- MACD
- KROS -0.01
- EU 0.02
- Stochastic Oscillator
- KROS 65.55
- EU 81.58
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.